Drug Hepatotoxicity, An Issue of Clinics in Liver Disease

Name: Drug Hepatotoxicity, An Issue of Clinics in Liver Disease
Brand: Elsevier
Price: 86.86 EUR
Availability: OnlineOnly

Vinod Rustgi(Autor*in)

Elsevier (Verlag)

1. Auflage

Erschienen am 16. November 2016

100 Seiten

E-Book

ePUB mit Adobe-DRM

Systemvoraussetzungen

978-0-323-49662-9 (ISBN)

86,86 €inkl. 7% MwSt.

Systemvoraussetzungen

für ePUB mit Adobe-DRM

E-Book Einzellizenz

Als Download verfügbar

Beschreibung

Weitere Details

Weitere Ausgaben

Inhalt

Intro
Title page
Table of Contents
Copyright
Contributors
Forthcoming Issues
Preface
Drug Metabolism in the Liver
Key points
Introduction
Drug metabolism pathways
Sites of drug metabolism
Factors affecting the metabolism of drugs
Summary
Drug-Induced Liver Disease: Clinical Course
Key points
Introduction
Discussion
Summary
Mechanisms of Drug-Induced Hepatotoxicity
Key points
Cell death (apoptosis and necrosis)
Reactive metabolite formation (bioactivation)
Drug transporter-mediated drug-induced hepatotoxicity
Immune-mediated response
Mitochondrial dysfunction
Activation of stress signaling pathways
Factors that contribute to drug-induced liver injury
Roussel Uclaf Causality Assessment Method
Summary
Epidemiology and Genetic Risk Factors of Drug Hepatotoxicity
Key points
Introduction
Epidemiology
Genetic associations with drug-induced liver injury
Summary
Adverse Drug Reactions: Type A (Intrinsic) or Type B (Idiosyncratic)
Key points
Introduction
Type A (intrinsic) adverse drug reactions
Type B (idiosyncratic) adverse drug reactions
Predicting drug-induced liver injury
Resources for clinicians
Evolution of drug-induced injury recognition and management
Other examples and management strategies for idiosyncratic drug-induced injury
Summary
Phenotypes and Pathology of Drug-Induced Liver Disease
Key points
Clinical syndromes and histologic correlates
Diagnosis of drug-induced liver disease
Morphologic features that suggest drug-induced liver injury
Drug Hepatotoxicity: Environmental Factors
Key points
Introduction
Geographic variation
Excessive alcohol consumption
Smoking
Infection and inflammation
Circadian rhythm and the hepatic clock
Gut microbiome
Environmental pollution
Summary
Drug Hepatotoxicity: Newer Agents
Key points
Introduction
Antibiotics
Molecular targeted therapy
Cardiovascular agents
Newer antidiabetic agents
Central nervous system agents
Herbal and Dietary Supplement-Induced Liver Injury
Key points
Introduction
Regulation and quality control
Clinical presentation and diagnosis
Pattern of injury
Unique aspects of herbal and dietary supplement-induced liver injury
Hepatotoxicity associated with specific herbal and dietary supplements
Proprietary mixes
Summary
Drug-Induced Acute Liver Failure
Key points
Introduction
Clinical features
Diagnosis
Management
Summary
Management of Acute Hepatotoxicity Including Medical Agents and Liver Support Systems
Key points
Introduction
Characterization of drug-induced liver injury
Management of drug-induced liver injury
Extracorporeal liver support systems
Summary
Drug Metabolism, Drug Interactions, and Drug-Induced Liver Injury in Living Donor Liver Transplant Patients
Key points
Introduction
Drug therapy in living donor liver transplant patients
Physiologic changes affecting pharmacokinetics after living donor liver transplant
Pharmacokinetic changes in living donor liver transplant
Pharmacokinetics of certain medications in living donor liver transplant patients
Idiosyncratic drug-induced liver injury in the living donor liver transplant setting
Hepatotoxicity of frequently used drugs in living donor liver transplant recipients and drug interactions
Summary
Evolution of Experimental Models of the Liver to Predict Human Drug Hepatotoxicity and Efficacy
Key points
Current status of drug hepatotoxicity prediction using mammalian in vivo models
In vitro models for predicting drug-induced hepatotoxicity
Past experiences with in vitro liver absorption, distribution, metabolism, excretion, and toxicity models predicting human clinical toxicity
Zebrafish larvae as a low-cost, medium-throughput, whole-organism platform to predict drug hepatotoxicity
Case study: using "fit-for-purpose" assay evaluations to rank-order compounds
Emergence of human tissue and organ models
Prospectus: moving to the future: integrating the human liver on a chip, computational models, and quantitative systems pharmacology

Systemvoraussetzungen

Als PDF speichern Als Link merken